A Sudbury biomedical firm is receiving $250,000 from the Northern Ontario Heritage fund for ongoing research to develop a vaccine for a bacterium that can cause stomach cancer.
Considered “groundbreaking research,” Lilly Creek Vaccines is working with the National Research Council of Canada to develop and test a vaccine that will fight the bacterium, H.pylori. The bacteria live in the digestive tract and can lead to ulcers, gastritis and stomach cancer.
Lilly Creek is a subsidiary of the Advanced
Medical Research Institute of Canada, a Sudbury medical research
institute.
”We are delighted with this investment that will
assist us with building a Sudbury-based, globally recognized
biotechnology company,” said Lilly Creek CEO Sean Thompson in an
Oct. 30 news release.
“Finding a vaccine for H.pylori will have major positive health impacts, globally, and help maintain Canada's place as a world leader in health research and innovation,” said Eric Hoskins, Minister of Health and Long-term Care.
